# Outcomes Following Neoadjuvant Immunotherapy for Oral Cavity Cancer: A Propensity Score Matched Analysis of the National Cancer Database

Daniel R. S. Habib BA<sup>1</sup>, Matthew Shou BA<sup>1</sup>, Christopher Naranjo BA<sup>1</sup>, Feyisayo O. Adegboye BA<sup>2</sup>, Ramez H. Philips MD<sup>3</sup>, Patrick Tassone MD MS<sup>4</sup>, Alexander J. Langerman MD SM<sup>2</sup>, Aimal Khan MD<sup>2</sup>, Michael C. Topf MD MSCl<sup>2</sup>

<sup>1</sup> Vanderbilt University School of Medicine, <sup>2</sup> Vanderbilt University Medical Center, <sup>3</sup> University of Chicago Medicine, <sup>4</sup> University of Missouri Health Care


#### Introduction

- There has been recent interest in the use of neoadjuvant immunotherapy (NI) prior to definitive resection of oral cavity squamous cell carcinoma (OCSCC).<sup>1,2</sup>
- There remains limited understanding of the effect of NI on surgical outcomes and overall survival (OS).<sup>2</sup>
- **Objective**: Determine associations between NI and postoperative outcomes as well as OS following OCSCC resection.

## Population / Design

- Population: National Cancer Database (NCDB) OCSCC surgery patients
- Statistical Analysis:
  - Chi-square / Wilcoxon rank-sum tests of postoperative outcomes by NI
  - 1:3 propensity score matching, Kaplan-Meier survival analysis, and Cox proportional-hazards analysis of patients with and without NI
- Covariates: Age, sex, race, insurance, treatment facility type and case volume, Charlson-Deyo Comorbidity Index, clinical T/N stage, neoadjuvant/adjuvant chemotherapy, postoperative radiation

Adults ≤90 years old with curative-intent surgery and neck dissection from 2010-2020 for OCSCC without distant metastasis (N=46,970)



### Main Outcomes / Measures

- Postoperative outcomes:
  - 30-day mortality
  - Unplanned 30-day readmission
  - Hospital length of stay (LOS)
  - Surgical margin status
  - Days to postoperative radiation
- Overall survival (OS)

#### Results

Table 1. Matched Cohort Postoperative Outcomes by Neoadjuvant Immunothera					
NI (N=255)	No NI (N=710)	P Value			
3 (1.2%)	6 (0.8%)	.705	N.I		
11 (4.3%)	38 (5.4%)	.517	N		
8 [6-11]	8 [6-12]	.994	Sl		
27 (10.6%)	103 (14.5%)	.116	m		
49 [42-61]	52 [42-62]	.296	p		
	NI (N=255) 3 (1.2%) 11 (4.3%) 8 [6-11] 27 (10.6%)	NI (N=255) No NI (N=710)  3 (1.2%) 6 (0.8%)  11 (4.3%) 38 (5.4%)  8 [6-11] 8 [6-12]  27 (10.6%) 103 (14.5%)	NI (N=255)       No NI (N=710)       P Value         3 (1.2%)       6 (0.8%)       .705         11 (4.3%)       38 (5.4%)       .517         8 [6-11]       8 [6-12]       .994         27 (10.6%)       103 (14.5%)       .116		

IQR: Interquartile range

No significant differences in surgical outcomes, positive margins, and time to postoperative radiation

Figure 1. Kaplan-Meier Survival Analysis by Neoadjuvant Immunotherapy




Table 2. Multivariable Cox Proportional-Hazards Analysis by Neoadjuvant Immunotherapy

Variable	Hazard Ratio (95% Confidence Interval)	P Value
Age	1.01 (1.00-1.02)	.113
Female Sex (vs Male)	0.94 (0.77-1.16)	.585
Race (vs White)		
Black	1.18 (0.76-1.86)	.462
Other	0.88 (0.48-1.62)	.689
Insurance		
Private/Managed Care	0.78 (0.45-1.33)	.356
Medicaid	1.31 (0.72-2.37)	.374
Medicare/Other Government	1.15 (0.65-2.02)	.629
Research/Academic Facility	0.98 (0.67-1.43)	.918
Top Quartile Facility Case Volume	1.18 (0.93-1.49)	.162
Charlson-Deyo Comorbidity Index (vs 0)		
1	1.2 (0.94-1.54)	.149
2+	1.35 (0.98-1.84)	.064
Clinical T Stage (vs cT1)		
cT2	0.81 (0.46-1.41)	.456
cT3	1.04 (0.58-1.85)	.901
cT4	1.19 (0.70-2.02)	.516
Clinical N Stage (vs cN0)		
cN1	1.22 (0.89-1.66)	.212
cN2-cN3	1.64 (1.30-2.09)	<.001
Neoadjuvant Immunotherapy	0.66 (0.51-0.84)	.001
<b>Neoadjuvant Chemotherapy</b>	1.44 (1.12-1.85)	.005
Adjuvant Chemotherapy	0.66 (0.51-0.84)	.001
Postoperative Radiation	1.34 (1.04-1.72)	.021

NI was independently associated with improved OS after controlling for matching variables.

# **Discussion / Conclusion**

- Limitations: Lack of specific adverse event data in NCDB and potential clinical trial enrollment bias
- NI does not significantly impact postoperative outcomes but is associated with improved OS.
- Though not yet standard of care, the OS benefit of NI may facilitate more effective individualized cancer care.

# References

- 1. Philips R, Han C, Swendseid B, et al. Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer. *Front Oncol.* 2021;11. doi:10.3389/fonc.2021.682075
- 2. Philips R, Alnemri A, Amin D, et al. Effect of preoperative programmed death-1 or programmed death ligand-1 immune check point inhibition on complications after surgery for primary head and neck cancer. *Cancer*. 2024;130(6):863-875. doi:10.1002/cncr.35045

